VKTXViking Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Viking Therapeutics, Inc. against SPDR S&P Biotech ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VKTXThis | $3.9B#14 | — | 9.7x#3 | — | — | -227.1%#13 | — | -88.1%#8 | — | — | — | — |
| MDGL | $12.4B#4 | — | 22.9x#10 | 13.0x#3 | 432.1%#2 | 38.1%#4 | -31.3%#5 | -53.0%#6 | -45.7%#3 | — | 82.8%#8 | — |
| TGTX | $8.4B#10 | 19.2x#1 | 14.4x#6 | 13.6x#4 | 87.3%#6 | 1811.1%#1 | 20.0%#3 | 76.7%#1 | 13.9%#1 | — | 55.4%#10 | — |
| INSM | $22.6B#1 | — | 32.0x#11 | 37.2x#7 | 66.7%#7 | -39.7%#8 | -205.6%#7 | -181.1%#11 | -185.1%#5 | 4#1 | -0.9%#13 | — |
| SRRK | $5.9B#13 | — | 21.4x#9 | — | — | -53.7%#10 | — | -137.0%#9 | -901.6%#6 | — | 32.3%#12 | — |
| APGE | $10.0B#6 | — | — | — | — | -40.5%#9 | — | — | — | — | 253.7%#3 | — |
| PTGX | $8.8B#9 | — | 13.4x#5 | 191.3x#9 | -89.4%#10 | -147.3%#12 | -343.6%#8 | -19.9%#4 | -33.5%#2 | — | 148.7%#5 | — |
| SMMT | $10.0B#7 | — | 15.9x#7 | — | — | -387.8%#14 | — | -171.4%#10 | — | — | -53.0%#14 | — |
| UTHR | $22.2B#2 | 19.3x#2 | 3.8x#1 | 7.0x#2 | 10.6%#8 | 11.7%#5 | 46.9%#2 | 22.6%#2 | — | — | 76.0%#9 | — |
| PRAX | $8.2B#11 | — | 5.9x#2 | — | -100.0%#11 | -65.6%#11 | — | -21.5%#5 | — | — | 429.9%#2 | — |
| ARWR | $12.1B#5 | — | 19.7x#8 | 14.6x#5 | 23258.2%#1 | 99.7%#3 | 11.9%#4 | -0.3%#3 | — | — | 438.9%#1 | — |
| COGT | $6.9B#12 | — | 11.4x#4 | 882.3x#10 | -65.0%#9 | -28.6%#6 | -4235.3%#10 | -54.1%#7 | -81.2%#4 | — | 243.6%#4 | — |
| BBIO | $16.7B#3 | — | — | 33.4x#6 | 126.3%#4 | — | -104.2%#6 | — | — | — | 84.7%#7 | 0.0%#1 |
| PTCT | $625M#15 | — | — | 0.4x#1 | 114.5%#5 | 288.0%#2 | 50.1%#1 | — | — | — | 52.7%#11 | — |
| CYTK | $9.9B#8 | — | — | 112.3x#8 | 376.6%#3 | -33.2%#7 | -695.4%#9 | — | — | — | 121.6%#6 | — |
Peer set: top holdings of XBI (SPDR S&P Biotech ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-07-30.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice